These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37865911)

  • 1. Re: Patel et al.: A cost-effectiveness analysis of pegcetacoplan for the treatment of geographic atrophy. (Ophthalmol Retina. 2024;8:25-31).
    Shen LL; Del Priore LV
    Ophthalmol Retina; 2024 Feb; 8(2):e3. PubMed ID: 37865911
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Vogl et al.: Predicting topographic disease progression and treatment response of pegcetacoplan in geographic atrophy quantified by deep learning (Ophthalmol Retina. 2023;7:4-13).
    Fukuyama H; Fawzi AA
    Ophthalmol Retina; 2023 Jul; 7(7):e11-e12. PubMed ID: 37204369
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of Pegcetacoplan With Progression of Incomplete Retinal Pigment Epithelium and Outer Retinal Atrophy in Age-Related Macular Degeneration: A Post Hoc Analysis of the FILLY Randomized Clinical Trial.
    Nittala MG; Metlapally R; Ip M; Chakravarthy U; Holz FG; Staurenghi G; Waheed N; Velaga SB; Lindenberg S; Karamat A; Koester J; Ribeiro R; Sadda S
    JAMA Ophthalmol; 2022 Mar; 140(3):243-249. PubMed ID: 35113137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan.
    Steinle NC; Pearce I; Monés J; Metlapally R; Saroj N; Hamdani M; Ribeiro R; Rosenfeld PJ; Lad EM
    Am J Ophthalmol; 2021 Jul; 227():116-124. PubMed ID: 33675755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study.
    Liao DS; Metlapally R; Joshi P
    Immunotherapy; 2022 Sep; 14(13):995-1006. PubMed ID: 35860926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
    Wykoff CC; Rosenfeld PJ; Waheed NK; Singh RP; Ronca N; Slakter JS; Staurenghi G; Monés J; Baumal CR; Saroj N; Metlapally R; Ribeiro R
    Ophthalmology; 2021 Sep; 128(9):1325-1336. PubMed ID: 33711380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
    Heier JS; Lad EM; Holz FG; Rosenfeld PJ; Guymer RH; Boyer D; Grossi F; Baumal CR; Korobelnik JF; Slakter JS; Waheed NK; Metlapally R; Pearce I; Steinle N; Francone AA; Hu A; Lally DR; Deschatelets P; Francois C; Bliss C; Staurenghi G; Monés J; Singh RP; Ribeiro R; Wykoff CC;
    Lancet; 2023 Oct; 402(10411):1434-1448. PubMed ID: 37865470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-Effectiveness Analysis of Pegcetacoplan for the Treatment of Geographic Atrophy.
    Patel NA; Al-Khersan H; Yannuzzi NA; Lin J; Smiddy WE
    Ophthalmol Retina; 2024 Jan; 8(1):25-31. PubMed ID: 37572871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
    Liao DS; Grossi FV; El Mehdi D; Gerber MR; Brown DM; Heier JS; Wykoff CC; Singerman LJ; Abraham P; Grassmann F; Nuernberg P; Weber BHF; Deschatelets P; Kim RY; Chung CY; Ribeiro RM; Hamdani M; Rosenfeld PJ; Boyer DS; Slakter JS; Francois CG
    Ophthalmology; 2020 Feb; 127(2):186-195. PubMed ID: 31474439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Minimizing risks to patients by improving presentation of clinical trial results in geographic atrophy trials (Ophthalmol Retina. 2022;6:337-338).
    Liao DS; Grossi FV; Wykoff CC; Ribeiro RM; Rosenfeld PJ; Sadda SR
    Ophthalmol Retina; 2022 Nov; 6(11):1109. PubMed ID: 36334931
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Teo et al.: Geographic atrophy phenotypes in subjects of different ethnicity: Asia-Pacific Ocular Imaging Society Work Group Report 3 (Ophthalmol Retina. 2023;7:593-604).
    Chong V
    Ophthalmol Retina; 2023 Jul; 7(7):e9-e10. PubMed ID: 37086258
    [No Abstract]   [Full Text] [Related]  

  • 12. Pegcetacoplan: First Approval.
    Hoy SM
    Drugs; 2021 Aug; 81(12):1423-1430. PubMed ID: 34342834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avacincaptad pegol (Izervay) for geographic atrophy in age-related macular degeneration.
    Med Lett Drugs Ther; 2024 Jan; 66(1694):15-16. PubMed ID: 38212259
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration (Ophthalmology. 2021;128:576-586).
    Pfau M
    Ophthalmology; 2021 Dec; 128(12):e219. PubMed ID: 34600774
    [No Abstract]   [Full Text] [Related]  

  • 15. Predicting Topographic Disease Progression and Treatment Response of Pegcetacoplan in Geographic Atrophy Quantified by Deep Learning.
    Vogl WD; Riedl S; Mai J; Reiter GS; Lachinov D; Bogunović H; Schmidt-Erfurth U
    Ophthalmol Retina; 2023 Jan; 7(1):4-13. PubMed ID: 35948209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegcetacoplan (Syfovre) for geographic atrophy in age-related macular degeneration.
    Med Lett Drugs Ther; 2023 Apr; 65(1673):49-50. PubMed ID: 37020339
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Jaffe et al.: C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2/3 trial (Ophthalmology. 2021;128:576-586).
    Keenan TDL
    Ophthalmology; 2021 May; 128(5):e25-e26. PubMed ID: 33551286
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of Fundus Autofluorescence Versus Optical Coherence Tomography-based Evaluation of the Therapeutic Response to Pegcetacoplan in Geographic Atrophy.
    Mai J; Riedl S; Reiter GS; Lachinov D; Vogl WD; Bogunovic H; Schmidt-Erfurth U
    Am J Ophthalmol; 2022 Dec; 244():175-182. PubMed ID: 35853489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement inhibitors for age-related macular degeneration.
    Tzoumas N; Riding G; Williams MA; Steel DH
    Cochrane Database Syst Rev; 2023 Jun; 6(6):CD009300. PubMed ID: 37314061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Pegcetacoplan Treatment on Photoreceptor Maintenance in Geographic Atrophy Monitored by Artificial Intelligence-Based OCT Analysis.
    Riedl S; Vogl WD; Mai J; Reiter GS; Lachinov D; Grechenig C; McKeown A; Scheibler L; Bogunović H; Schmidt-Erfurth U
    Ophthalmol Retina; 2022 Nov; 6(11):1009-1018. PubMed ID: 35667569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.